Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144) (NCT02360579)

This study is intended to determine whether patients with metastatic melanoma will benefit from adoptive cell therapy (ACT) using their own tumor infiltrating lymphocytes (TILs).

TILs are a type of immune cell that can fight cancer. Patients will undergo a chemotherapy regimen, and then researchers will extract a tumor sample. The sample will be cultured in the laboratory to increase the number of TILs. Later, patients are reinfused with the autologous TILs (LN-144).

Iovance Biotherapeutics sponsors this study.